Emergent Biosolutions Inc. diskutieren
Emergent Biosolutions Inc.
WKN: A0LC2W / Symbol: EBS / Name: Emergent Bio / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
9,66 €
22,33 %
Emergent BioSolutions Inc. (NYSE: EBS) was upgraded by analysts at Benchmark Co. from a "hold" rating to a "buy" rating. They now have a $22.00 price target on the stock.
Ratings data for EBS provided by MarketBeat
Emergent BioSolutions Inc. (NYSE: EBS) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co..
Ratings data for EBS provided by MarketBeat
Emergent BioSolutions Inc. (NYSE: EBS) was upgraded by analysts at Benchmark Co. from a "hold" rating to a "buy" rating. They now have a $5.00 price target on the stock.
Ratings data for EBS provided by MarketBeat
Emergent BioSolutions Inc. (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $5.00 price target on the stock.
Ratings data for EBS provided by MarketBeat
Emergent BioSolutions Inc. (NYSE: EBS) had its price target raised by analysts at Benchmark Co. from $5.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for EBS provided by MarketBeat
Emergent BioSolutions Inc. (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $8.00 price target on the stock.
Ratings data for EBS provided by MarketBeat
Emergent BioSolutions Inc. (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $8.00 price target on the stock.
Ratings data for EBS provided by MarketBeat
Emergent BioSolutions Inc. (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $8.00 price target on the stock.
Ratings data for EBS provided by MarketBeat
Neueste Beiträge
Raymond_James in Regency Centers diskutieren